Veera Raghava Chowdary Palacharla

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

• In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations
  Drug Metabolism and Disposition 2026 DOI: 10.1016/j.dmd.2026.100295
  +Save
• Determination of Intrinsic Clearance and Fraction Unbound in Human Liver Microsomes and In Vitro-In Vivo Extrapolation of Human Hepatic Clearance for Marketed Central Nervous System Drugs
  European Journal of Drug Metabolism and Pharmacokinetics 2025 DOI: 10.1007/s13318-024-00931-2
  +Save
• Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
  Clinical Drug Investigation 2022 DOI: 10.1007/s40261-022-01189-9
  +Save
• Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
  Alzheimer's & dementia (New York, N. Y.) 2022 DOI: 10.1002/trc2.12307
  +Save
• Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
  Psychopharmacology 2022 DOI: 10.1007/s00213-022-06108-6
  +Save
• Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease
  Journal of Medicinal Chemistry 2021 DOI: 10.1021/acs.jmedchem.1c00703
  +Save
• First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
  Clinical drug investigation 2021 DOI: 10.1007/s40261-021-01027-4
  +Save
• The use of inactivated brain homogenate to determine the in vitro fraction unbound in brain for unstable compounds
  Xenobiotica 2020 DOI: 10.1080/00498254.2020.1771795
  +Save
• Absorption, Distribution, Metabolism, Excretion (ADME), Drug-drug interaction potential and Prediction of Human Pharmacokinetics of SUVN-G3031, a Novel Histamine 3 Receptor (H3R) inverse agonist in Clinical development for the treatment of Narcolepsy
  European Journal of Pharmaceutical Sciences 2020 DOI: 10.1016/j.ejps.2020.105425
  +Save
• Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses
  Clinical Drug Investigation 2020 DOI: 10.1007/s40261-020-00920-8
  +Save